Vandetanib (ZD6474)

For research use only.

Catalog No.S1046

90 publications

Vandetanib (ZD6474) Chemical Structure

CAS No. 443913-73-3

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).

Selleck's Vandetanib (ZD6474) has been cited by 90 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).
Targets
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)
40 nM 110 nM 500 nM
In vitro

Vandetanib also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Vandetanib is not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM, while almost has no activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib inhibits VEGF-, EGF- and bFGF-stimulated HUVEC proliferation with IC50 of 60 nM, 170 nM and 800 nM, with no effect on basal endothelial cell growth. Vandetanib inhibits tumor cell growth with IC50 of 2.7 μM (A549) to 13.5 μM (Calu-6). [1] Vandetanib displays an inhibitory effect on the basal ABCG2-ATPase. Parental and ABCG2-expressing A431 cells showed similar sensitivities toward Vandetanib. Exposure to EGFR inhibitors decreases pEGFR levels in A431 cells, with Vandetanib displaying only a moderate effect. Vandetanib displays a slight but measurable effect, whereas gefitinib, pelitinib and neratinib completely inhibit ABCG2-mediated efflux of mitoxantrone from A431/ABCG2 cells, similarly to the specific ABCG2 inhibitor Ko143. [2] Vandetanib inhibits both PC3wt and PC3R cell lines with similar IC50 of 13.3 μM and 11.5 μM, respectively. [3] Vandetanib suppresses phosphorylation of VEGFR2 in HUVEC and EGFR in hepatoma cells and inhibits cell proliferation. [4] Vandetanib causes an accumulation of cells in the G0-G1 phases in GEO and OVCAR-3 cells and increases apoptosis in OVCAR-3, ZR-75-1, MCF-10A ras, and GEO cells. Vandetanib causes a dose-dependent inhibition of EGFR phosphorylation in mouse NIH-EGFR fibroblasts and human MCF-10A ras breast cancer cells, two cell lines that overexpress the human EGFR. Vandetanib treatment results in a dose-dependent inhibition of soft agar growth in seven human cell lines (breast, colon, gastric, and ovarian) with functional EGFR but lacking VEGFR2. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SN179  Ml;sSpVv[3Srb36gRZN{[Xl? NFvNcJk2ODEkgJnuUeKh NXHZcphUOTZiaB?= M1TjXIlv[3KnYYPld{BEYEOUNDDlfJBz\XO|aX;uJJNq\26rZnnjZY51dHl? NYfZcHBRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2O|Y3QTFpPkK1Olc3PjlzPD;hQi=>
SN186 M{\WVGZ2dmO2aX;uJGF{e2G7 NFO3Tnc2ODEkgJnuUeKh MoPHNVYhcA>? NEj1eI5qdmO{ZXHz[ZMhS1iFUkSg[ZhxemW|c3nvckB{cWewaX\pZ4FvfGy7 MoHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4N{[2PVEoRjJ3Nke2OlkyRC:jPh?=
SN179  Mlr5SpVv[3Srb36gRZN{[Xl? NVXufIFkPTBy4pEJcm3DqA>? NXLXW2ZpOTZiaB?= MmjY[Y5p[W6lZYOgeIhmKEO[Q1yxNkBlcXKnY4Tl[EBucWe{YYTpc44> MlfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4N{[2PVEoRjJ3Nke2OlkyRC:jPh?=
SN179  MVrGeY5kfGmxbjDBd5NigQ>? Mkj5OVAx6oDLbl5CpC=> MYSxOkBp NFzHVIpqdmO{ZXHz[ZMh[mG|YXygcYloemG2aX;uxsA> NGrld5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[3OlY6OSd-MkW2O|Y3QTF:L3G+
Jurkat MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfqc5o4OsLiaNMg MVrHTVUxRTFwNTFCtUAxNjJizszN MkDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEGyNFUoRjJ2NkixNlA2RC:jPh?=
K-562 NFvoT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPaO|LDqGkEoB?= MXHHTVUxRTFwODFCtUAxNjFizszN MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6MUKwOUc,OjR4OEGyNFU9N2F-
NCTC-2544 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LQT|czyqCqwrC= M4DnfWdKPTB;ND62JOKyKDBwMzFOwG0> Moi3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEGyNFUoRjJ2NkixNlA2RC:jPh?=
A-431 NEHsTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfjRpE4OsLiaNMg M1npXWdKPTB;Mj60JOKyKDBwMzFOwG0> MnLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEGyNFUoRjJ2NkixNlA2RC:jPh?=
SK-N-SH NYm2cVNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV2wMlYzPS1{MDFOwG0> NYK2bWEzPDhiaB?= M4rDfWROW09? NVfjSmNtcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHrobW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5PVA4PCd-MkSzPVkxPzR:L3G+
SH-SY5Y NFfJbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvJOXIxNjZ{NT2yNEDPxE1? NVjQVnVPPDhiaB?= NHK3UmdFVVOR NUfXXnNEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4rQTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m5NFc1Lz5{NEO5PVA4PDxxYU6=
SK-N-SH MoXmRZBweHSxc3nzbUBCe3OjeR?= M3rxNlUwOTBxMkCg{txO NVnV[ItsPDhiaB?= Mnj4SG1UVw>? M{DQfYlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NHHJPGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5PVA4PCd-MkSzPVkxPzR:L3G+
SH-SY5Y M{jkUWFxd3C2b4Ppd4khSXO|YYm= MlG4OU8yOC9{MDFOwG0> NGjRUWc1QCCq MWjEUXNQ MXfpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NUnPNItlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVkxPzRpPkK0N|k6ODd2PD;hQi=>
SK-N-SH NXHJToI6TnWwY4Tpc44hSXO|YYm= MkO5OU8yOC9{MDFOwG0> MYe0PEBp MUXEUXNQ NHHkcG5qdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0 MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7OUC3OEc,OjR|OUmwO|Q9N2F-
SH-SY5Y MUnGeY5kfGmxbjDBd5NigQ>? MW[1M|ExNzJyIN88US=> M1O5cFQ5KGh? NUD4VVZHTE2VTx?= MljybY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dB?= M{nzeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m5NFc1Lz5{NEO5PVA4PDxxYU6=
SK-N-SH NXjqfnJMTnWwY4Tpc44hSXO|YYm= Mm\BNU82NzFyIN88US=> NVLpco9PPDhiaB?= MoX2SG1UVw>? MWjpcohq[mm2czDSSXQheGixc4Doc5J6dGG2aX;u M2fEfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m5NFc1Lz5{NEO5PVA4PDxxYU6=
SH-SY5Y NYnxOHE5TnWwY4Tpc44hSXO|YYm= M1nufFEwPS9zMDFOwG0> Mor3OFghcA>? NYPhZnY5TE2VTx?= NXzadJd3cW6qaXLpeJMhWkWWIIDoc5NxcG:{eXzheIlwdg>? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7OUC3OEc,OjR|OUmwO|Q9N2F-
SK-N-SH MX;GeY5kfGmxbjDBd5NigQ>? MmXwOU8yOCEQvF2= MVG0PEBp M4TmUWROW09? NWDuNnVCcW6qaXLpeJMhcHWvYX6gUmIh[2WubDDtbYdz[XSrb36= M1qxS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m5NFc1Lz5{NEO5PVA4PDxxYU6=
SH-SY5Y NVjsfng6TnWwY4Tpc44hSXO|YYm= NXfmUmxMPS9zMDFOwG0> NISwZZI1QCCq MYLEUXNQ MXvpcohq[mm2czDoeY1idiCQQjDj[YxtKG2rZ4LheIlwdg>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7OUC3OEc,OjR|OUmwO|Q9N2F-
SK-N-SH NVHXV|U4TnWwY4Tpc44hSXO|YYm= MoH2OU8yOCEQvF2= MVW0PEBp MWfEUXNQ NYqxW4lkcW6qaXLpeJMhcHWvYX6gUmIh[2WubDDpcpZie2mxbh?= MmPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OUmwO|QoRjJ2M{m5NFc1RC:jPh?=
SH-SY5Y MnK3SpVv[3Srb36gRZN{[Xl? NHvlPYw2NzFyIN88US=> NEDmR5E1QCCq MmDnSG1UVw>? MXPpcohq[mm2czDoeY1idiCQQjDj[YxtKGmwdnHzbY9v MluxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OUmwO|QoRjJ2M{m5NFc1RC:jPh?=
SK-N-SH M2PqO2Z2dmO2aX;uJGF{e2G7 MVq1JO69VQ>? M3zpWFI1NzR6L{eyJIg> M4jSVmROW09? MVPzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNZS1J2IHHu[EBOVVBzNDDtVm5C M2\vbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m5NFc1Lz5{NEO5PVA4PDxxYU6=
SH-SY5Y NYnsTZRWTnWwY4Tpc44hSXO|YYm= MUi1JO69VQ>? NWjQT2lQOjRxNEivO|IhcA>? MlywSG1UVw>? NFS3OpJ{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEO[Q2K0JIFv\CCPTWCxOEBuWk6D MmrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OUmwO|QoRjJ2M{m5NFc1RC:jPh?=
SK-N-SH MmHvSpVv[3Srb36gRZN{[Xl? NYP2VIJrPSEQvF2= NYOyNmlMPDhxN{KgbC=> MonwSG1UVw>? NUHhUXY2e3WycILld5NmeyCneIDy[ZN{cW:wIH;mJJRp\SCFWFPSOEBidmRiTV3QNVQheHKxdHXpci=> NXLhOJZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVkxPzRpPkK0N|k6ODd2PD;hQi=>
SH-SY5Y NVvTR3ZiTnWwY4Tpc44hSXO|YYm= NXjMcWFIPSEQvF2= MnzOOFgwPzJiaB?= NVj4WHc3TE2VTx?= MkH2d5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIITo[UBEYEOUNDDhcoQhVU2SMUSgdJJwfGWrbh?= MnzVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OUmwO|QoRjJ2M{m5NFc1RC:jPh?=
HMEpC NXTmeFBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOxJI5ONTFyMDFOwG0> NGPWeVc1QMLiaNMg MlW0SG1UVw>? MY\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NX7jflNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN|g5PDNpPkK0NVM5QDR|PD;hQi=>
MCF-7 NEj3c2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz4PYkxOSCwTT2xNFAh|ryP M1vEO|Q5yqCqwrC= NGrpOYFFVVOR MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF|OEi0N{c,OjRzM{i4OFM9N2F-
ZR-75-1 NV\OWpYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M336WVEhdk1vMUCwJO69VQ>? MnXoOFjDqGkEoB?= NEn6dlVFVVOR MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Ml3sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{i4OFMoRjJ2MUO4PFQ{RC:jPh?=
MDA-MB-231 NIrvSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xJI5ONTFyMDFOwG0> NEH0UZI1QMLiaNMg MmXnSG1UVw>? M2\YWIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF|OEi0N{c,OjRzM{i4OFM9N2F-
MDA-MB-468 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF25N4syKG6PLUGwNEDPxE1? NIXVfIk1QMLiaNMg MkfZSG1UVw>? NFvmflBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NEDs[GE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzPFg1Oyd-MkSxN|g5PDN:L3G+
T-47-D MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmOwNUBvVS1zMECg{txO M3frSlQ5yqCqwrC= NVLXZmpQTE2VTx?= MnLHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MljSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{i4OFMoRjJ2MUO4PFQ{RC:jPh?=
U251  M4rtU2Z2dmO2aX;uJGF{e2G7 M2LHUVIwPC964pEJ{tzjjLQEoB?= NFi4bI83NzF{L{K0JIg> MYXEUXNQ MV3pcoNz\WG|ZYOgeIhmKEyFMz3JTUBt\X[nbDDpckBiKHSrbXWt[IVx\W6mZX70JIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYn4PYdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3PVk5PTJpPkKzO|k6QDV{PD;hQi=>
U87MG NX7HWYgxTnWwY4Tpc44hSXO|YYm= NWPjXnlzOi92L{lihKnPxOLGs9Mg MVq2M|EzNzJ2IHi= NFzCcpNFVVOR MV;pcoNz\WG|ZYOgeIhmKEyFMz3JTUBt\X[nbDDpckBiKHSrbXWt[IVx\W6mZX70JIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGOwXYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5PVg2Oid-MkO3PVk5PTJ:L3G+
U251  MXnGeY5kfGmxbjDBd5NigQ>? MlywOQKBkc7:4pUzxsA> NUHqWZluOi94L{GyJIg> NGjwZopFVVOR MVnzeZBxemW|c3XzJIJie2GuIHzleoVteyCxZjDwbI9{eGixconsZZRqd25ib3[gV|YhMFN{M{WvNlM3MSxiNFWtRnAyKCiWM{evOFYqNCCjbnSgRYt1KCiVNEezLUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7lduKh MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7OUi1Nkc,OjN5OUm4OVI9N2F-
U87MG NEXBNYdHfW6ldHnvckBCe3OjeR?= NYi4VFFKPOLCid885qS{yqB? NX\iV2pUOi94L{GyJIg> MXXEUXNQ NFrmcVR{fXCycnXzd4V{KGKjc3HsJIxmfmWuczDv[kBxcG:|cHjvdplt[XSrb36gc4YhWzZiKGOyN|UwOjN4KTygOGUuSlBzIDjUN|cwPDZrLDDhcoQhSWu2IDjTOFc{MSCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5mesLi MkXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUm4OVIoRjJ|N{m5PFUzRC:jPh?=
H1650  NWrCUFBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;yblR7UUN3ME2zMlXDuTFwMjFOwG0> NHTReXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K3OFc2QCd-MkOyO|Q4PTh:L3G+
HUVECs  Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\mZlg4OiCq NUXGW2wzUUN3MNMgQUA4NjFizsztc4wwVA>? MnriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MUGwNlcoRjJ{NkGxNFI4RC:jPh?=
KYN-2  NYXYfId7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPXbVA4OiCq NHr1NGRKSzVywrC9JFgvOSEQvH3vcE9N Mon5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MUGwNlcoRjJ{NkGxNFI4RC:jPh?=
HuH-7  NHPsfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7yO|IhcA>? NGXwR4VKSzVywrC9JFkvPCEQvH3vcE9N M3XsSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkGxNFI4Lz5{Mk[xNVAzPzxxYU6=
HUVECs  NWXTPWpETnWwY4Tpc44hSXO|YYm= M1nTSFEwPS9zMDFOwG0> MX6xJIg> NE[ybHJ{cWewaX\pZ4FvfGy7IHnubIljcXS|IG\FS2ZTNTJicHjvd5Bpd3K7bHH0bY9v MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZzMUCyO{c,OjJ4MUGwNlc9N2F-
HAK1-B NF:xdG5HfW6ldHnvckBCe3OjeR?= NH6wRWcyNzVxMUCg{txO NXTBOWpHOSCq NEWxeZN{fXCycnXzd4V{KEWJRmKgdIhwe3Cqb4L5cIF1cW:w MonEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MUGwNlcoRjJ{NkGxNFI4RC:jPh?=
UM-22A M2[2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWwMVYh|ryP NF3TbFE4OiCq MV7EUXNQ MWLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXHySIhNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNFc4OzVpPkKyN|A4PzN3PD;hQi=>
UM-22B M{PoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HDflAuPiEQvF2= MYi3NkBp M{TYTmROW09? NH3kV4VqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MoLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|MEe3N|UoRjJ{M{C3O|M2RC:jPh?=
PCI-37A NUn4b|JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nyNlAuPiEQvF2= NVXMWXJ3PzJiaB?= M4mxfmROW09? NXzmfIZUcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4fmSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
PCI-37B NUGzd4U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnRNE03KM7:TR?= NYjrZ4NwPzJiaB?= NEHFUY5FVVOR NUPSc5Z[cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4T5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
PCI-15B NYHTenV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL0NE03KM7:TR?= MYG3NkBp MnflSG1UVw>? M3nZfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NF3Lb|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOwO|c{PSd-MkKzNFc4OzV:L3G+
SCC-25 M4rHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDHdY5bOC14IN88US=> M3:xcVczKGh? M3jJTGROW09? MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NIXhUIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOwO|c{PSd-MkKzNFc4OzV:L3G+
UM-22A M4H2TGZ2dmO2aX;uJGF{e2G7 Mlz6NE0yOCEQvF2= NVq5UHlCOjRiaB?= MlHDSG1UVw>? NImxbG5qdmirYnn0d{B1cGViYXP0bZZifGmxbjDv[kB1cGViRVfGVkB1gXKxc3nu[UBscW6jc3WgZY5lKGGuc3:g[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIH\vdo1{KG:oIITo[UBld3ewc4Ty[YFuKHOrZ37hcIlv\yCnbHXt[Y51eyxiU2TBWFMh[W6mIF3BVGs> M{jlOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
UM-22B NHHoWItHfW6ldHnvckBCe3OjeR?= MlzkNE0yOCEQvF2= NULzRYxnOjRiaB?= MmnaSG1UVw>? NWO3[WxqcW6qaXLpeJMhfGinIHHjeIl3[XSrb36gc4YhfGinIFXHSnIhfHm{b4PpcoUhc2mwYYPlJIFv\CCjbIPvJIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDmc5JueyCxZjD0bIUh\G:5boP0doVidSC|aXfuZYxqdmdiZXzlcYVvfHNuIGPURXQ{KGGwZDDNRXBM MonzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|MEe3N|UoRjJ{M{C3O|M2RC:jPh?=
PCI-15B NHfRSYpHfW6ldHnvckBCe3OjeR?= NVXZXmJ5OC1zMDFOwG0> NFjVeXgzPCCq NEHwS|NFVVOR NYToUId5cW6qaXLpeJMhfGinIHHjeIl3[XSrb36gc4YhfGinIFXHSnIhfHm{b4PpcoUhc2mwYYPlJIFv\CCjbIPvJIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDmc5JueyCxZjD0bIUh\G:5boP0doVidSC|aXfuZYxqdmdiZXzlcYVvfHNuIGPURXQ{KGGwZDDNRXBM M3LOSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
PCI-37A NED1[3hHfW6ldHnvckBCe3OjeR?= MXuxJO69VQ>? Mn7hNlQhcA>? NHPWPWZFVVOR Mn73[I94dnKnZ4XsZZRmeyCYRVfGJJBzd2S3Y4Tpc44> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNyN{ezOUc,OjJ|MEe3N|U9N2F-
UM-22A NHSzeHBHfW6ldHnvckBCe3OjeR?= MlLLNUDPxE1? M4PxfVI1KGh? MXzEUXNQ MWDkc5dvemWpdXzheIV{KF[HR1[gdJJw\HWldHnvci=> NXrudGtyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNFc4OzVpPkKyN|A4PzN3PD;hQi=>
PCI-15B NEXB[JVHfW6ldHnvckBCe3OjeR?= NYjIcmd5OSEQvF2= NITwNGUzPCCq NF\LUJpFVVOR NIrpSYlld3ewcnXneYxifGW|IG\FS2YheHKxZIXjeIlwdg>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNyN{ezOUc,OjJ|MEe3N|U9N2F-
PCI-15B NFrvdVlKdn[jc3nvckBCe3OjeR?= M2TkUFI1KGh? MkTNSG1UVw>? MVrFR|UxRTV3ODDuUS=> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNyN{ezOUc,OjJ|MEe3N|U9N2F-
PCI-37A MoHHTY53[XOrb36gRZN{[Xl? NFHUUWszPCCq NUPCR2Z3TE2VTx?= NVfub|dJTUN3ME2xOlk2KG6P M2jqSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
UM-22A MVzJcpZie2mxbjDBd5NigQ>? MlPkNlQhcA>? NWfHZ5F[TE2VTx?= M2raOmVEPTB;MD6zJI5O M1rBd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
SCC-25 Mn7qTY53[XOrb36gRZN{[Xl? NEiyRWkzPCCq NHr3T25FVVOR Mn7tSWM2OD1zMDDuUS=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNyN{ezOUc,OjJ|MEe3N|U9N2F-
UM-22B MnvTTY53[XOrb36gRZN{[Xl? NF;NNo4zPCCq NUXXelZITE2VTx?= MU\FR|UxRTJ2MkSgcm0> M3H2PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
PCI-37B MUnJcpZie2mxbjDBd5NigQ>? MUGyOEBp NFTyU|dFVVOR MXnFR|UxRTF5Mk[gcm0> M1:5R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
201T M2nXcWZ2dmO2aX;uJGF{e2G7 MWiyMlUh|ryP NX7KVGwyPDhiaB?= NF3vRWRFVVOR MVfpcohq[mm2czDwbI9{eGixLV3BVGsh\m:ubH;3bY5oKEWJRh?= M{nP[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkW4OFc3Lz5{MkK1PFQ4PjxxYU6=
273T  NF7JbYNHfW6ldHnvckBCe3OjeR?= MUCyMlUh|ryP M{PLU|Q5KGh? NGfFfJRFVVOR NIf1PVZqdmirYnn0d{BxcG:|cHjvMW1CWEtiZn;scI94cW6pIFXHSi=> NXzKeldqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVg1PzZpPkKyNlU5PDd4PD;hQi=>
A549 NHrOdYtHfW6ldHnvckBCe3OjeR?= MX:yMlUh|ryP NYKzWIFXPDhiaB?= MmDxSG1UVw>? MVrpcohq[mm2czDwbI9{eGixLV3BVGsh\m:ubH;3bY5oKEWJRh?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ3OES3Okc,OjJ{NUi0O|Y9N2F-
201T  Ml;qSpVv[3Srb36gRZN{[Xl? NHG4XJUyNzVxMUCg{txO MWG0PEBp NXXFTmU5TE2VTx?= NGrPSWhjdG:la4OgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgbY5lfWOnZDDifUBXTUeIQx?= NGHicGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK1PFQ4Pid-MkKyOVg1PzZ:L3G+
H2052 M3;mVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjmb3FKSzVyPUGuNFfDuTBwMESg{txO M3rwb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUewPFc1Lz5{MUm3NFg4PDxxYU6=
H2452 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXG[YFrUUN3ME2zMlUzyrFzLkGzJO69VQ>? NEC3WYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm3NFg4PCd-MkG5O|A5PzR:L3G+
H28 M1fjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrmT|B3UUN3ME2wMlMzyrFyLkC3JO69VQ>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl5MEi3OEc,OjF7N{C4O|Q9N2F-
MSTO-211H NXKx[mU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULJZnFzUUN3ME2xMlQzyrFyLkCzJO69VQ>? NEn1OHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm3NFg4PCd-MkG5O|A5PzR:L3G+
Hth83 NFmzdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[3NkBp M3f2XmROW09? NGXkNFBKSzVyPUOuN|AhyrFiMD62OkDPxE1? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ{MES3O{c,OjF{MkC0O|c9N2F-
C643 M1nIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnpVXVbPzJiaB?= NVz3TXAxTE2VTx?= Ml7vTWM2OD1|Lk[1JOKyKDFwMkKg{txO Mn\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MkC0O|coRjJzMkKwOFc4RC:jPh?=
8505C MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjPRY5PPzJiaB?= M2L5OGROW09? NY\pNGRRUUN3ME23MlU3KMLzIEGuNVMh|ryP M1ezelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkKwOFc4Lz5{MUKyNFQ4PzxxYU6=
Hth74 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrLO|IhcA>? NV31cFJ4TE2VTx?= MYXJR|UxRThwNU[gxtEhOS5yMTFOwG0> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ{MES3O{c,OjF{MkC0O|c9N2F-
SW1736 NED6OY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPRe2Y4OiCq MUnEUXNQ Mlv5TWM2OD17LkC1JOKyKDBwNUWg{txO NIf1SmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKyNFQ4Pyd-MkGyNlA1Pzd:L3G+
Hth7 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTvSVVKPzJiaB?= NX\UR3l3TE2VTx?= NFfBeo1KSzVyPUmuOlYhyrFiMD6zPEDPxE1? NX;Lc45YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNlA1PzdpPkKxNlIxPDd5PD;hQi=>
Hth104 M1XkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\xV|czKGh? MV;EUXNQ MUnJR|UxRcLzMU[uPVghyrFiTlGg{txO MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ{MES3O{c,OjF{MkC0O|c9N2F-
HTB3 M3XRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7TNE0zOCEQvF2= NIfFe4szPMLiaB?= MkD3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NFvSeWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNFI2Pid-MUmyNlAzPTZ:L3G+
HT1376 NFnISFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXPUpExNTJyIN88US=> MnW0NlTDqGh? M3n4[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NH3zbI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNFI2Pid-MUmyNlAzPTZ:L3G+
RT4 NXjTdZFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7jNE0zOCEQvF2= M13TeVI1yqCq NYO0eoh3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MmHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkCyOVYoRjF7MkKwNlU3RC:jPh?=
J82 NITuU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOwMVIxKM7:TR?= NH\ub5UzPMLiaB?= NYPvV2lCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MEK1Okc,OTl{MkCyOVY9N2F-
CRL1749 M4Tm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:wMVIxKM7:TR?= MUmyOOKhcA>? NWrq[GpOcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MEK1Okc,OTl{MkCyOVY9N2F-
T24 NUTrRWJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nYXFAuOjBizszN M2XE[|I1yqCq M3n5VolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MEK1Okc,OTl{MkCyOVY9N2F-
SUP MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLYZ3MxNTJyIN88US=> MnXFNlTDqGh? NH3heZZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHTaOYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNFI2Pid-MUmyNlAzPTZ:L3G+
HTB9 M{XLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnPT4g1OC1{MDFOwG0> MYOyOOKhcA>? MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M1rWW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKwNlU3Lz5zOUKyNFI2PjxxYU6=
ACC3 MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H5TVAuOTBizszN NGDmRlY4OiCq M3zDOolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MoXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUiwNlUoRjF6Nkm4NFI2RC:jPh?=
ACC2 Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MViwMVExKM7:TR?= NXXwe2d[PzJiaB?= MkP5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mmi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUiwNlUoRjF6Nkm4NFI2RC:jPh?=
ACCM NVvtc5JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXFNE0yOCEQvF2= MYm3NkBp MVHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7OECyOUc,OTh4OUiwNlU9N2F-
ACC3 NYnyemZ7SXCxcITvd4l{cSCDc4PhfS=> M1LvTFAuOTBizszN MlzXO|IhcA>? MUDpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NVvkclJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVgxOjVpPkG4Olk5ODJ3PD;hQi=>
ACC2 M4Ls[GFxd3C2b4Ppd4khSXO|YYm= MVGwMVExKM7:TR?= MUW3NkBp MlnsbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= M{L3dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nkm4NFI2Lz5zOE[5PFAzPTxxYU6=
ACCM NH:5cFFCeG:ydH;zbZNqKEG|c3H5 M{XpW|AuOTBizszN MV[3NkBp MYfpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NYm5Z|ZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVgxOjVpPkG4Olk5ODJ3PD;hQi=>
EHMES-1 MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnlZWlnPzJiaB?= M2DP[GROW09? NHP2d3pKSzVyPUGwMlYh|ryP NFnqTWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO2OFI1QCd-MUizOlQzPDh:L3G+
EHMES-10 NUTLV5lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHKO|IhcA>? M37OSmROW09? MojKTWM2OD1yLkOg{txO NF\ZcpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO2OFI1QCd-MUizOlQzPDh:L3G+
211H MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3jO|IhcA>? MnrFSG1UVw>? M3nyZWlEPTB;Mj6yJO69VQ>? NHHuN4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO2OFI1QCd-MUizOlQzPDh:L3G+
H28 Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLXO|IhcA>? Ml\OSG1UVw>? NWL4NY1bUUN3ME2xMlgh|ryP M2rOW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{[0NlQ5Lz5zOEO2OFI1QDxxYU6=
H2052 MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT4RotOPzJiaB?= MmmxSG1UVw>? M4n0[WlEPTB;OD6wJO69VQ>? M4\tb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{[0NlQ5Lz5zOEO2OFI1QDxxYU6=
H2452 M3THTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn3PXNTPzJiaB?= MmTBSG1UVw>? M3vuVGlEPTB;NT61JO69VQ>? M3HVXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{[0NlQ5Lz5zOEO2OFI1QDxxYU6=
CNE-1 M{XEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XRPVAvOS1{NT62JO69VQ>? MVW0PEBp MUnJR|UxRTNwNjFOwG0> NVTOUG9JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2N|E3PDZpPkG3OlMyPjR4PD;hQi=>
CNE-2 NGGybHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzDUXU4OC5zLUK1MlYh|ryP NGPYb5g1QCCq NUjW[mNxUUN3ME22MlIh|ryP Mn7YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4M{G2OFYoRjF5NkOxOlQ3RC:jPh?=
C666-1 M3vRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LmWlAvOS1{NT62JO69VQ>? NY\RU3pwPDhiaB?= M2PkZWlEPTB;MkOuOEDPxE1? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ|MU[0Okc,OTd4M{G2OFY9N2F-
CNE-1 M2nifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKwMlEuOjVwNjFOwG0> MYK3NkBp NHPuWoFKSzVyPUKuN{DPxE1? NITwOpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[zNVY1Pid-MUe2N|E3PDZ:L3G+
CNE-2 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rDfFAvOS1{NT62JO69VQ>? MkTUO|IhcA>? NYj0V2xJUUN3ME2zMlYh|ryP MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ|MU[0Okc,OTd4M{G2OFY9N2F-
C666-1 NXrBW4dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DrTlAvOS1{NT62JO69VQ>? MnfYO|IhcA>? M4LYU2lEPTB;ND64OkDPxE1? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ|MU[0Okc,OTd4M{G2OFY9N2F-
CNE-1 M{LrWWZ2dmO2aX;uJGF{e2G7 MmCzOkDPxE1? M{fvN|I1KGh? MUDk[YxigXNiR{CvS|Eh[2WubDDjfYNt\SCycn;ndoV{e2mxbh?= NFTh[2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[zNVY1Pid-MUe2N|E3PDZ:L3G+
CNE-2 MWHGeY5kfGmxbjDBd5NigQ>? NI\RSXQ3KM7:TR?= MmTNNlQhcA>? MYHk[YxigXNiR{CvS|Eh[2WubDDjfYNt\SCycn;ndoV{e2mxbh?= MkCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4M{G2OFYoRjF5NkOxOlQ3RC:jPh?=
C666-1 M1;UWmZ2dmO2aX;uJGF{e2G7 NWDpW3JNPiEQvF2= Mmr5NlQhcA>? Mnvs[IVt[Xm|IFewM2cyKGOnbHygZ5lkdGVicILv[5Jme3Orb36= M2DrNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkOxOlQ3Lz5zN{[zNVY1PjxxYU6=
KDR15 M3zMVmZ2dmO2aX;uJIF{e2G7 Mn64TY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JHZGT0Zic4TpcZVt[XSnZDDheZRweGixc4Doc5J6dGG2aX;uJI9nKF[HR1\SNkBmgHC{ZYPz[YQhcW5iS1TSNVUh[2WubIOsJGlEPTBiPTCwMlAyPSEQvF2u NGfVbFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkOwNlc6Pyd-MU[zNFI4QTd:L3G+
Sf9 NW\HSoFyTnWwY4Tpc44h[XO|YYm= NGLUb21KdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IHjpd5Rq\GmwZT30ZYdo\WRiUlXUJEg4ODBvMUCyNEkh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDifUBGVEmVQTygTWM2OCB;IECuNFk4KM7:TT6= M3m4PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEC5OlE5Lz5{MESwPVYyQDxxYU6=
TPC1 NF20[YpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M3zCdlczKGi{cx?= MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFSSQ{GgZ4VtdHNiZYjwdoV{e2mwZzDSSXQwWEOWMTDh[pRmeiB5MjDodpMh[nliW{PIYZRpgW2rZHnu[UBqdmOxcoDvdoF1cW:wIHHzd4F6NCCLQ{WwJF0hOC5zMU[g{txONg>? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyOU[xPEc,OjB2MEm2NVg9N2F-
HEK293 MXPGeY5kfGmxbjDhd5NigQ>? NVnofFBFUW6qaXLpeIlwdiCxZjDGS2ZTOS:YRVfGVlIh[2irbXXybYMh[2:wc4TyeYN1KGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[nliRVzJV2EtKEWGNUCgQUAxNjF3IN88UU4> NHHPWIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGwNVE2PSd-MUmxNFEyPTV:L3G+
Sf21 NGGycm9HfW6ldHnvckBie3OjeR?= MojCNVUhdWmwcx?= Mo\pTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDIbZMufGGpZ3XkJIh2dWGwIFvEVkBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoMkGgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB{MDDtbY5{KGK7IFjUVmYh[XO|YYmsJGlEPTBiPTCwMlE4PSEQvF2u MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh5NEe0NUc,OjZ6N{S3OFE9N2F-
umbilical vein endothelial cells M3\HSGZ2dmO2aX;uJIF{e2G7 MlW2TY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgdJJwdGmoZYLheIlwdiCxZjDoeY1idiC3bXLpcIlk[WxidnXpckBmdmSxdHjlcIlidCClZXzsd{whUUN3MDC9JFAvPCEQvF2u M4[3XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3N{SzNlAzLz5zNUe0N|IxOjxxYU6=
BA/F3 MlniSpVv[3Srb36gZZN{[Xl? M2PINFQ5KGi{cx?= NVTKOIt{UW6qaXLpeIlwdiCxZjDLTWY2Si:URWSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hdW:3c3WgRmEwTjNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCFZXzsJJRqfHKnIHfsc{1j[XOnZDDseY1qdmW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlQh|ryPLh?= Mlv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6N{S3OFEoRjJ4OEe0O|QyRC:jPh?=
BA/F3 NXS4WZY6TnWwY4Tpc44h[XO|YYm= MkHZOFghcHK| MljLTY5pcWKrdHnvckBw\iCNRGKgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hdW:3c3WgRmEwTjNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCFZXzsJJRqfHKnIHfsc{1j[XOnZDDseY1qdmW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlY{KM7:TT6= NYHG[pk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4O|Q4PDFpPkK2PFc1PzRzPD;hQi=>
umbilical vein endothelial cells NIP1PW1HfW6ldHnvckBie3OjeR?= MlLVTY5pcWKrdHnvckBw\iCkYYPpZ{BHT0ZvaX7keYNm\CCycn;sbYZmemG2aX;uJI9nKGi3bXHuJJVu[mmuaXPhcEB3\WmwIHXu[I91cGWuaXHsJINmdGy|LDDJR|UxKD1iMT6yJO69VS5? M3ToUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3N{SzNlAzLz5zNUe0N|IxOjxxYU6=
HL60 MnPZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MlXIO|IhcHK| NGPpRY9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuOFkzKM7:TT6= NXjNT4NkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PVU2OjdpPkK2PVk2PTJ5PD;hQi=>
293 NYewTYdKTnWwY4Tpc44h[XO|YYm= M{n3NGlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBXTUeIUkKgeJJidnOrZX70cJkhfHKjboPm[YN1\WRiaX6gNlk{KGGmZX7veolzfXNidILhcpNn\WO2ZXSgb4lldmW7IHPlcIx{KGK7IFXMTXNCNCCLQ{WwJF0hOS54NjFOwG0v NH7D[4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkK3OVA4Oid-MU[yO|UxPzJ:L3G+
293 Mn\zSpVv[3Srb36gZZN{[Xl? Mo\UTY5pcWKrdHnvckBw\iCYRVfGVlIhcW5iMkmzJIFl\W6xdnnyeZMhfHKjboPm[YN1\WRia3nkcoV6KGOnbHzzJIJ6KGOnbHytZoF{\WRiRVzJV2Eh[XO|YYmsJGlEPTBiPTCxMlY3KM7:TT6= NYTiTZNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[zNlE2OzFpPkG2N|IyPTNzPD;hQi=>
HEK293 M1zXRmZ2dmO2aX;uJIF{e2G7 NVriW4N[UW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKGmwIFjFT|I6OyClZXzsd{BjgSClZXzsMYJie2WmIFXMTXNCNCCLQ{WwJF0hOS54NjFOwG0v NH3XRVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS2NFk{Pid-MU[0OlA6OzZ:L3G+
HT-29 MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NV[zO2xzPzJiaILz M4jncWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuPVI2KM7:TT6= M4jIOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUm1OVI4Lz5{Nkm5OVUzPzxxYU6=
DU145 MlW2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NIS3dmo4OiCqcoO= MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLkm3OEDPxE1w NETzWFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm5OVUzPyd-Mk[5PVU2Ojd:L3G+
MGHU3 M3vwWmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 Mn;JO|IhcHK| NXHsWVUySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNS2hWOyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFIvPSEQvF2u NU\PeXZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzNFk3PzFpPkOwN|A6PjdzPD;hQi=>
A549 NFHPenBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXK3NkBpenN? Mly1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR|UxKD1iMj61JO69VS5? MlPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|MEm2O|EoRjNyM{C5OlcyRC:jPh?=
RT112 MVXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NVrIWFZvPzJiaILz M1TCXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmSxNVIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmsJGlEPTBiPTCyMlUh|ryPLh?= M37HU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{C5OlcyLz5|MEOwPVY4OTxxYU6=
A549 MVjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M{\UVFczKGi{cx?= NGHNVXNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuOlMh|ryPLh?= M{T5U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUm1OVI4Lz5{Nkm5OVUzPzxxYU6=
CHO M3[yNWZ2dmO2aX;uJIF{e2G7 MYrJcohq[mm2aX;uJI9nKF[HR1\SJIlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckBw\iCqdX3hckBX[XOldXzhdkBmdmSxdHjlcIlidCCpcn;3eIgh\mGldH;yJJJm[2WydH;yJFIhMF[HR1\SNkkhfHKjboPm[YN1\WRiaX6gR2hQKGOnbHzzMEBKSzVyIE2gNk43PzNizszNMi=> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjR5N{O1Nkc,OTJ2N{ezOVI9N2F-
MCF7 MonnRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NXjDXXc1PzJiaILz NHTrR3BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEOuOVM3KM7:TT6= NHyzWVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm5OVUzPyd-Mk[5PVU2Ojd:L3G+
PANC1 MX3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mn\UO|IhcHK| MnHVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQV7DNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iND6xNFch|ryPLh?= MmPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7OUW1NlcoRjJ4OUm1OVI4RC:jPh?=
HT-29 MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NF3RT5UyOCC3TR?= NXnze2NKPzJiaILz NF75ZWpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIF1KDFyIIXNJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTBiPTC0MlIh|ryPLh?= M3;IZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{WzOVQ3Lz5{MUO1N|U1PjxxYU6=
EAhy926 NHHjSINCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NUWxfplCOTBidV2= NXTqeVN7PzJiaILz MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWDaIm5NlYh[2WubIOgZZQhOTBidV2gZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEWuNUDPxE1w MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN3M{W0Okc,OjF|NUO1OFY9N2F-
MCF7 M4jqXGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NH;1e2c1QCCqcoO= M17VWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDt[YF{fXKnZDDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMUGuPFMh|ryPLh?= Mlf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4OEixPFAoRjJ5Nki4NVgxRC:jPh?=
MCF7 NIPE[YdEgXSxdH;4bYNqfHliYYPzZZk> MnPJOFghcHK| M4K1bWN6fG:2b4jpZ4l1gSCrbjDoeY1idiCPQ1[3JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigbY5kfWKjdHXkJIZweiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMU[uOVIh|ryPLh?= NFnmTnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm0NlEyOyd-Mki5OFIyOTN:L3G+
MCF7 M2\3emFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M{XEd|Q5KGi{cx?= MkTZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzOD61JO69VS5? NH;q[YE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke0NVM2QCd-Mk[3OFE{PTh:L3G+
MCF7 NXPXb2c6SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MUG0PEBpenN? NWnBNXB2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxPE42KM7:TT6= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NUWxPUc,OjZ2N{W1NVk9N2F-
HT-29 M13LXGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NVf2XmdlPDhiaILz MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy|IH3lZZN2emWmIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzOD65OUDPxE1w NHnGSFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[4PFE5OCd-Mke2PFgyQDB:L3G+
H460 MkLjRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NF73NYw1QCCqcoO= NWnH[5pLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJI1m[XO3cnXkJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCzO{4yKM7:TT6= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZ6OEG4NEc,Ojd4OEixPFA9N2F-
A673 M1nH[ZFJXFNiYYPzZZk> M2PC[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY NUfVcWhIeUiWUzDhd5NigQ>? MnqzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NW[2OFg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MlOxdWhVWyCjc4PhfS=> MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? NGXDUIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MVnxTHRUKGG|c3H5 MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> NHS2NYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH M13repFJXFNiYYPzZZk> NIey[mJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> NHTUeIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) MWrxTHRUKGG|c3H5 MmTRdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| M1n5eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 NIK2UpZyUFSVIHHzd4F6 NHHiNpFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz Mn3aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NWLoOJZieUiWUzDhd5NigQ>? NHW4eI9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz M2rXN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH MY\xTHRUKGG|c3H5 MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{ NYDoR4h6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 MoG1dWhVWyCjc4PhfS=> NEjLTI1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= MmfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 MnnUdWhVWyCjc4PhfS=> M2\JOZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MmTudWhVWyCjc4PhfS=> NInqOW1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> M3zFe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 NYG2NZMyeUiWUzDhd5NigQ>? MmfsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| NX\pdm57RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18 NFzVPWRyUFSVIHHzd4F6 MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? M3\EPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR ; 

PubMed: 20629091     


Dose-dependent inhibition of EGFR phosphorylation by vandetanib in the human HNSCC cell lines FaDu, and SCC61. Cells were serum-starved, treated for 90 min with vandetanib at the indicated concentrations, and then stimulated for 15 min with 50 ng/ml EGF. Whole-cell lysates were obtained and subjected to Western immunoblotting to resolve proteins. Antibodies to total (unphosphorylated) receptors and β-actin were used as protein loading controls.

p-ERK / ERK / p-AKT / AKT ; 

PubMed: 19622715     


Logarithmically growing U87 and T98G cells were incubated with varying concentrations of vandetanib for 24 h. The cells were lysed, and equal amounts of proteins were separated by SDS-PAGE and probed with specific antibodies against phospho-ERK, and phospho-Akt. Western blot analysis was performed as described under Materials and Methods. The blots were subsequently stripped and reprobed against total ERK, Akt, or β-actin. 

20629091 19622715
Growth inhibition assay
Cell viability; 

PubMed: 24261856     


(A) MTT assays of HUVEC with α-santalol, vandetanib or sunitinib, respectively. (B) MTT assays of PC-3 cells with α-santalol, vandetanib or sunitinib, respectively.

24261856
In vivo Vandetanib (2.5 mg/kg, i.v.), reverses a VEGF-induced hypotension by 63% but does not significantly affect a bFGF-induced hypotension. Vandetanib (100 mg/kg) inhibits the tumor-induced blood vessel formation by 79%. Vandetanib (12.5-100 mg/kg, orally) shows great tumor growth inhibition in human tumor xenografts including Calu-6, PC-3, MDA-MA-231, SKOV-3, SW620, A549, A431, B16-F10(AP3) and Lewis Lung, with little effects on body weight. [1] In PC3wt xenografts, administration of Vandetanib alone exerts paradoxical tumor growth stimulating effects. In PC3R xenografts, the low dose of Vandetanib (25 mg/kg) has no significant effect relative to control, whereas the high dose (50 mg/kg) significantly inhibits tumor growth compared with control. In contrast, the high-dose combination reveals a significant negative interaction between Vandetanib 50 mg/kg and docetaxel 30 mg/kg in PC3R cells. [3] In tumor-bearing mice, Vandetanib suppresses phosphorylation of VEGFR2 and EGFR in tumor tissues, significantly decreases tumor vessel density, enhances tumor cell apoptosis, suppresses tumor growth, improves survival, reduces number of intrahepatic metastases, and up-regulates VEGF, TGF-alpha and EGF in tumor tissues. Treatment with Vandetanib is not associated with serious adverse events, including ALT abnormality, bone marrow suppression or body weight loss. [4] Vandetanib treatment of nude mice bearing palpable GEO colon cancer xenografts (which are sensitive to inhibition of EGFR signaling) induces dose-dependent tumor growth inhibition. [5]

Protocol

Kinase Assay:

[1]

- Collapse

Kinase inhibition:

Vandetanib is incubated with enzyme, 10 mM MnCl2, and 2 μM ATP in 96-well plates coated with a poly(Glu, Ala, Tyr) 6:3:1 random copolymer substrate. Phosphorylated tyrosine is then detected by sequential incubation with a mouse IgG anti-phosphotyrosine 4G10 antibody, a horseradish peroxidase-linked sheep antimouse immunoglobulin antibody, and 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid). This methodology is adapted to examine selectivity versus tyrosine kinases associated with EGFR, PDGFRβ, Tie-2, FGFR1, c-kit, erbB2, IGF-1R, and FAK. All enzyme assays (tyrosine or serine-threonine) used appropriate ATP concentrations at or just below the respective Km (0.2–14 μM). Selectivity versus serine-threonine kinases (CDK2, AKT, and PDK1) is examined using a relevant scintillation proximity-assay (SPA) in 96-well plates. CDK2 assays contained 10 mM MnCl2, 4.5 μM ATP, 0.15 μCi of [γ-33 P]ATP/reaction, 50 mM HEPES (pH 7.5), 1 mM DTT, 0.1 mM sodium orthovanadate, 0.1 mM sodium fluoride, 10 mM sodium glycerophosphate, 1 mg/mL BSA fraction V, and a retinoblastoma substrate (part of the retinoblastoma gene, 792–928, expressed in a glutathione S-transferase expression system; 0.22 μM final concentration). Reactions are allowed to proceed at room temperature for 60 minutes before quenching for 2 hours with 150 μL of a solution containing EDTA (62 mM final concentration), 3 μg of a rabbit immunoglobulin anti-glutathione S-transferase antibody and protein A SPA-polyvinyltoluene beads (0.8 mg/reaction). Plates are then sealed, centrifuged (1200× g for 5 minutes), and counted on a Microplate scintillation counter for 30 seconds.
Cell Research:

[1]

- Collapse
  • Cell lines: Calu-6, PC-3, MDA-MA-231, SKOV-3, SW620, A549, A431, B16-F10(AP3) and Lewis Lung cells
  • Concentrations: 0.1–100 μM
  • Incubation Time: 72 hours
  • Method:

    Tumor cells are plated in their respective media at predetermined densities that are known to enable logarithmic cell growth during the period of assay (PC-3, 500 cells/well; all others, 1000 cells/well). Plates are incubated for 24 hours (37 °C with CO2) before the addition of Vandetanib (0.1–100 μM) or vehicle (0.1% DMSO in medium). Plates are reincubated for an additional 72 hours before assessing cell proliferation by [3 H]thymidine incorporation by a beta counter.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: Female athymic (nu/nu genotype) Swiss mice with PC-3, Calu-6, SKOV-3, and MDA-MB-231 tumors
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 50 mg/kg/day, or 100 mg/kg/day
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.41 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% CMC Na
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.35
Formula

C22H24BrFN4O2

CAS No. 443913-73-3
Storage powder
in solvent
Synonyms N/A
Smiles CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03291379 Completed Drug: BTG-002814 Carcinoma Hepatocellular|Metastatic Colorectal Cancer Boston Scientific Corporation|Biocompatibles UK Ltd May 17 2017 Early Phase 1
NCT02495103 Terminated Drug: Vandetanib|Drug: Metformin|Drug: Vandetanib/Metformin Renal Cell Carcinoma|Hereditary Leiomyomatosis|Renal Cell Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 26 2015 Phase 1|Phase 2
NCT02530411 Unknown status Drug: Fulvestrant|Drug: Vandetanib Neoplasms Velindre NHS Trust|Cancer Research UK|AstraZeneca April 2015 Phase 2
NCT02268734 Unknown status -- Metastatic Sporadic Medullary Thyroid Cancer Fondazione IRCCS Istituto Nazionale dei Tumori Milano April 2014 --
NCT01876784 Active not recruiting Drug: Vandetanib (SAR390530)|Drug: Placebo Differentiated Thyroid Cancer Genzyme a Sanofi Company|Sanofi September 17 2013 Phase 3
NCT01661179 Completed Drug: Vandetanib 300mg Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma Genzyme a Sanofi Company|Sanofi November 2012 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Vandetanib (ZD6474) | Vandetanib (ZD6474) supplier | purchase Vandetanib (ZD6474) | Vandetanib (ZD6474) cost | Vandetanib (ZD6474) manufacturer | order Vandetanib (ZD6474) | Vandetanib (ZD6474) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID